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Extra-cellular matrixExisting diagnostic guidelines for heart failure with preserved ejection fraction (HFPEF) primarily comprise
natriuretic peptides and echocardiographic assessment, highlighting the role of diastolic dysfunction. However,
recent discoveries of novel plasma markers implicated in pathophysiology of heart failure and technological
advances in imaging provide additional biomarkers which are potentially applicable to HFPEF. The evidence
base for plasma extra-cellular matrix (ECM) peptides, galectin-3, ST2, GDF-15 and pentraxin-3 is reviewed.
Furthermore, the capabilities of novel imaging techniques to assess existing parameters (e.g. left ventricular ejec-
tion fraction, systolic & diastolic function, chamber size) and additional derangements of the ECM, myocardial
mechanics and ischaemia evaluation are addressed.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Heart failure with preserved ejection fraction (HFPEF) is the subtype
of heart failure (HF) most likely to be encountered in clinical practice in
the near future and already accounts for approximately half of all HF
cases [1]. Yet importantly, we appear no closer to offering effective
treatments [2]. The latest HFPEF diagnostic guidelines [3] were
published nearly eight years ago and still remain subject to debate. In
the intervening period, technological advances in the ﬁelds of plasma
biomarkers and imaging have further improved our understanding of
this heterogeneous entity, provided insights into potential targets for
therapy and improved diagnostic labeling. We review the respective
merits of these newer biomarkers and consider their applicability for
future use in HFPEF frameworks.2. Current limitations, potential challenges and the need for
biomarker development in HFPEF
A biomarker has been deﬁned as a “characteristic that is objectively
measured and evaluated as an indicator of normal biological processes,
pathogenic processes or pharmacologic responses to a therapeutic
intervention” [4]. Themedical condition of interest should: be sufﬁcientlylar Sciences, Glenﬁeld Hospital,
le.ac.uk (I.B. Squire),
McCann).
land Ltd. This is an open access articlcommon, signiﬁcantly impact upon morbidity & mortality, be well
deﬁned and with effective treatments available. Likewise, for the
biomarker being developed, it should ideally: be a stable product, dis-
criminate between pathology and normal (and between pathologies),
enhance clinical care, be acceptable to patients, exhibit a linear relation
with change in pathology as well as being reproducible and replicated
across multiple studies [5].
Adopting this approach to HFPEF reveals a series of disease- and
biomarker-speciﬁc factors (see Table 1) that make biomarker develop-
ment challenging [2,3,6–9]. The primary limiting factor is the marked
heterogeneity that characterizes HFPEF populations. To date, various
diagnostic criteria (including differing ejection fraction [EF] thresholds)
have been employed to deﬁneHFPEF. Phenotypic diversity (e.g. obesity,
diabetes, atrial ﬁbrillation, right heart failure) coupled with a high
prevalence of co-morbidities makes patient identiﬁcation difﬁcult.
Imaging phenocopies such as hypertrophic cardiomyopathy and
amyloid are additional confounders. Alternate explanations for patho-
physiological mechanisms add to the uncertainty. Furthermore, the
discriminatory capabilities of biomarkers (to distinguish HFPEF from
heart failure with reduced ejection fraction [HFREF]) are hindered by
supportive evidence to suggest the existence of both entities in contin-
uum as part of a single syndrome. While invasive pressure assessments
best illustrate the haemodynamic consequences of diastolic dysfunction
(DD), they are limited by inherent procedural risks. On the other hand,
non-invasivemeasures of DD arewithin normal range in up to a third of
subjects. These factors highlighted above therefore ensure that existing
and newer markers described in this article do not wholly fulﬁll the
aforementioned biomarker criteria [10–16].e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Challenges and limitations of existing biomarkers in HFPEF.
Disease speciﬁc factors
Population not well deﬁned [2]
Variable diagnostic criteria in guidelines and clinical trials [2]
Confounders of diagnosis [7,8]
Phenotypic variability
High prevalence of co-morbidities may alternatively explain clinical features
Imaging phenocopies (e.g. hypertrophic cardiomyopathy, amyloid, pericardial
constriction)
Atrial ﬁbrillation (challenging clinical and imaging assessment)
No clear and effective therapies available [2]
Evidence for HFPEF as a continuum with HFREF [3,6,7]
Similar clinical signs and symptoms
Unimodal distribution of EF in clinical trials
Co-existence of systolic abnormalities and progression over time
Eccentric remodeling over time seen in hypertensives
Heterogeneity of pathophysiology [6,7,9]
Diastolic dysfunction — in HFPEF & HFREF, in normal subjects, absent in≈1/3 of
HFPEF
Alternate abnormalities of: ventricular–arterial coupling, arterial stiffness,
systemic & pulmonary vasculature, chronotropic incompetence, endothelial
function, LA function volume overloading, LV systolic function
Biomarker speciﬁc factors
Invasive approach (assessment of diastolic dysfunction or biopsy quantiﬁcation
of ﬁbrosis)
Procedural risk
Sampling error
Non-uniform responses in end-diastolic pressure volume relationship curves
Traditional echocardiographic measures for diagnosis [10–15,43]
Not the recognized gold standard for EF, LV & LA volumes, LV mass
Limitations of methodology and feasibility, less reproducible compared to CMR
Markers of diastolic dysfunction: loading dependent
Haemodynamic disturbances may not be apparent at rest
Plasma natriuretic peptides [16]
Lower values in HFPEF versus HFREF
Lower values in obesity
Higher levels in non-HFPEF conditions but commonly encountered in HFPEF
Abbreviations: HFPEF = heart failure with preserved ejection fraction; HFREF = heart
failure with reduced ejection fraction; EF = ejection fraction; LA = left atrium; LV =
left ventricle.
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potential biomarkers
Various pathophysiological derangements have been implicated in
HFPEF (see Table 1). The central disturbance remains diastolic dysfunc-
tion,which in turn is governed bymyocardial stiffness [6,7]. Hypertensive
heart disease accounts for a signiﬁcant cohort ofHFPEF and is associated
with left ventricular hypertrophy (LVH), pressure overload, concentric
remodeling and myocardial ﬁbrosis. Structural remodeling results
in alterations in both the intra- (e.g. larger cardiomyocytes and predom-
inance of the stiffer isoform of the protein Titin) & extracellular com-
partments [6]. Stiffness is increased by ﬁbrosis resulting in reduced
left ventricular (LV) compliance and elevated LV ﬁlling pressuresTable 2
Summary of strengths and potential applicability of imaging biomarkers in HFPEF.
LVEF Contractile function
(LV/LA)
Chamber
quantiﬁcation
ECM quantiﬁcation
(ﬁbrosis)
M
m
TTE ++ ++ ++ + +
CMR +++ +++ +++ +++ +
PET + + + ++ n
SPECT + + + + n
CT + + +++ + +
Adapted from Paterson et al. [100] and Jellis et al. [50].
Abbreviations:HFPEF=heart failure with preserved ejection fraction; LVEF= left ventricular e
coronary artery disease; TTE= trans-thoracic echocardiography; CMR= cardiac magnetic reso
tomography; CT= computed tomography; n/a=not applicable or not assessed;+= limited e
study or registry data; +++= accepted reference standard or strongly supportive evidence bwhich are the haemodynamic hallmarks of HFPEF. Myocardial stiffness
is primarily determined by the turnover rates of the extra-cellular
matrix (ECM) and its constituents (predominantly collagen). However,
additional factors such as inﬂammatory processes, endothelial
dysfunction, ischaemia, and neurohormonal activation may contribute
[6,7,9,16,17]. These pathological changes and consequences may be
detectable by either plasma or imaging techniques (see Table 2 and
Supplementary online Table 1) and form the basis of subsequent sections.
4. Novel plasma biomarkers
4.1. ECM biomarkers
Matrix metalloproteinases (MMPs) primarily degrade collagen and
other ECM components while inhibitors of matrix metalloproteinases
(TIMPs) counteract their actions. Generally, in HFPEF, TIMPs are
increased and MMPs are decreased such that collagen degradation is
reduced and collagen accumulation is increased. Conversely, in HFREF
the opposite has been demonstrated [6,7,18]. However, the concept of
a high TIMP/MMP ratio being synonymous with HFPEF is too rigid
since individualMMPs and TIMPs also actively promote ﬁbrosis through
alternate (and additional) mechanisms of action [16]. The high levels of
MMPs−1 [19],−2 [20–22],−8 [22], and−9 [20,21] reported inHFPEF
likely reﬂect this phenomenon. In hypertensive subjects with HFPEF,
TIMP-1 moderately predicts the presence of HF with an area under
curve (AUC) of 0.71 and higher levels are detected compared to controls
[18]. Additionally, TIMP-1 levels correlate with DD and are reportedly
more accurate than NT-proBNP for detecting echocardiographic esti-
mates of elevated LV ﬁlling pressures using E/E′ [19].
Compared to controls, circulatingmarkers of active collagen turnover
i.e. synthesis (e.g. pro-collagen type I carboxy-terminal pro-peptide
[PICP] [19,22], collagen III N-terminal pro-peptide [PIIINP] [22]) and
degradation (e.g. collagen I telopeptide [CITP]) are elevated in HFPEF
[20,22,23]. Furthermore, elevated levels appear to correlate with wors-
ening indices of DD [19,20,22]. In a study of 446 subjects including
healthy controls (n = 241), LVH without HF (n = 144) and LVH with
HFPEF (n = 61), a multi-biomarker panel comprising MMP-7 & -9,
TIMP-1and PIIINP detected the presence of LVH (AUC = 0.8). A further
panel consisting of MMP-2 & -8, TIMP-4 and PIIINP best detected LVH
with HFPEF (AUC = 0.79) [22].
4.2. Galectin-3
Galectin-3 is a soluble β-galactoside binding protein secreted by
activated macrophages, promoting ﬁbroblast & myo-ﬁbroblast activity
and pro-collagen deposition in the ECM. Seminal studies in rat models
ﬁrst highlighted the potential role of Galectin-3 as a pro-ﬁbrotic and
pro-inﬂammatory mediator in HF [24]. While intra-pericardial infusion
of galectin-3 induced adverse cardiac remodeling and LV dysfunction,
these deleterious effectswere counteracted by administration of its inhib-
itor [25]. Enhanced galectin-3 expression induces ﬁbroblast proliferation,yocardial
echanics
Haemodynamics CAD/ischaemia/ﬂow
reserve
Molecular
imaging
Metabolic
imaging
+ +++ + n/a n/a
++ ++ +++ + ++
/a n/a +++ ++ ++
/a n/a ++ ++ ++
n/a + + n/a
jection fraction; LV= left ventricle; LA= left atrium; ECM=extra-cellular matrix; CAD=
nance; PET= positron emission tomography; SPECT= single-photon emission computed
vidence but potential future role;++=supportive evidence from either at least one large
ase including meta-analyses or randomized controlled trials.
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elevated serum levels are associatedwith an increased risk of HF develop-
ment [27],worsening grades of DD [28] and adverse outcomes [27,29]. In-
terestingly, despite similar levels of Galectin-3 measured in both HFPEF
and HFREF, increased serum concentrations appear to be a stronger pre-
dictor of mortality in HFPEF (n = 114). However, this observation is lim-
ited by the small sample size used and a lower EF threshold (N 40%) for
deﬁning HFPEF [30].
4.3. Inﬂammatory processes, endothelial dysfunction and neurohormonal
activation
4.3.1. ST2
The ST2 receptor is a member of the Interleukin-1 family existing in
trans-membrane and soluble forms. ST2 modulates inﬂammatory sig-
naling and neurohormonal activation in HF. Soluble ST2 (sST2) acts as
a decoy receptor disrupting the binding of interleukin-33 and promotes
excess cardiac ﬁbrosis, hypertrophy and LV dysfunction [31]. In both
HFPEF and HFREF, ST2 secretion by vascular endothelium is enhanced
in response to elevated left ventricular end-diastolic pressure (LVEDP)
measured by cardiac catheterization. Furthermore, the rise in ST2 levels
is proportional to increasing values of LVEDP [32].
In acute HF, increased ST2 levels correlate with worsening HF
symptoms, mortality at one-year and confer incremental prognostic
value compared to NT-pro-BNP [33]. As a diagnostic aid in chronic,
stable hypertensive patients (n = 107) recruited from the out-patient
setting, sST2 performed better than NT-pro BNP (AUC = 0.80 versus
AUC = 0.70) [34] for the detection of HFPEF (n = 68). In a further
prospective study assessing risk (n = 447), ST2 levels while compara-
tively lower in HFPEF than HFREF, remained an independent predictor
of mortality [35].
4.3.2. Growth differentiating factor-15 (GDF-15)
GDF-15 is amember of the transforming growth factor-β cytokine su-
perfamily and is also expressed by activated macrophages. Although not
normally expressed inmyocardium, it can be induced in response tomet-
abolic stress such as cardiac ischaemia, pressure overloador inﬂammation
[36]. In apparently healthy, elderly individuals from the community (n=
1004, age N 70), GDF-15 independently predicted HF development and
rising levels correlated with higher LV mass and concentric hypertrophy
[37]. In a small population study (n = 151), the discriminatory capacity
of GDF-15 (AUC = 0.936) was similar to NT-proBNP (AUC = 0.934) for
HFPEF versus controls. Increasing levels of both biomarkers correlated
with worsening diastolic indices. A ratio of NT-pro BNP: GDF-15 best dis-
tinguished HFPEF from HFREF (AUC = 0.709) [38].
4.3.3. Pentraxin-3
As part of a superfamily of proteins including C-reactive protein
(CRP) and serumamyloid protein (SAP), Pentraxin-3 has become recog-
nized as an inﬂammatory marker in HF. When exposed to pressure
overload, pentraxin-3 expression is increased in wild type mice. Con-
versely, cardiac hypertrophy, ﬁbrosis and LV dysfunction are attenuated
in pentraxin-3 knockout mice [39]. In a study inclusive of both subtypes
of HF (total n = 196), elevated plasma pentraxin-3 correlated with
advancing NHYA grade and was a strong, independent predictor of ad-
verse cardiac events in multivariate analysis also incorporating BNP
(AUC = 0.8047 versus 0.7107) [40]. In a further study, pentraxin-3
levels were signiﬁcantly higher inHFPEF (n= 82) compared to controls
and independently correlated with the presence of DD (as measured by
E/E′) in both groups [41].
While all the aforementioned candidate biomarkers have shown
promise in studyingHFPEF, ST2 and Galectin-3 appear closest to routine
clinical application at present. These markers are the most extensively
evidence based, provide prognostic data and better identify those at
risk of developing incident HF. However, prospective studies in HFPEFevaluating plasma biomarker guided management and treatments are
currently lacking with all [42].
5. Novel imaging biomarkers
5.1. Quantiﬁcation of the ECM (surrogate measures of DD)
5.1.1. Echocardiography
Traditional echocardiographic parameters used to diagnose HFPEF
(e.g. E/E′, E/A ratio, LA volume, LV mass) are reliant on assessing
the resting functional and structural consequences of ﬁbrosis (see
Table 1). Beyond ischaemia evaluation, diastolic stress echocardiogra-
phy may further unmask patients with HFPEF in whom resting ﬁlling
pressures do not meet current diagnostic criteria but rise with exercise
(E/E′ N 15) [43]. However, indirect assessment of ﬁbrosis is also possible
via echocardiography. Collagen content governs the elasticity of
myocardial tissue thereby altering its acoustic impedence, density and
reﬂectivity in response to ultrasound signals used in echocardiography
[44]. Using the pericardium as an internal control, these integrated
signals scatter back (IBS) to the imaging probe permitting estimates of
regional ﬁbrotic burden.
Myocardial reﬂectivity is enhanced in ﬁbrosis and conditions associ-
ated with the phenotype of HFPEF (e.g. hypertension, chronic renal
failure [45] and obesity [46]). Furthermore, indices of IBS have been
validated against biopsy measured collagen content in non-ﬁbrotic
myocardium [44] and interstitial ﬁbrosis in hypertensive subjects [47].
Signiﬁcant correlations have been shown with plasma ECM biomarkers
[48], Doppler echocardiographicmeasures [45,46] and increasing sever-
ity of DD [49]. Currently, ﬁbrosis assessment by echocardiography
remains subject to limitations of limited acoustic windows, low signal-
to-noise, operator skill and the reproducibility is unknown.
5.1.2. Cardiac magnetic resonance (CMR)
Focal myocardial ﬁbrosis is detectable by echocardiography, comput-
ed tomography (CT), single-photon emission computed tomography
(SPECT) and CMR with reasonable agreement in all [50,51]. CMR late
gadolinium enhancement (LGE) imaging was initially developed upon
an understanding that infarcted (scarred) myocardium is associated
with regional increases in collagen content, extra-cellular volume
(ECV) expansion and a slower washout of extra-cellular contrast agents
(e.g. gadolinium) from such areas. Due to the accumulation of gadolini-
um based contrast agents in these areas T1 times (relaxation properties
of tissue) are reduced such that ﬁbrotic regions appear as areas of high
signal intensity compared to ‘nulled’ (black) normal myocardium using
inversion recovery CMR sequences [13]. CMR LGE is the accepted gold
standard due to its superior spatial resolution and high contrast-to-
noise ratio enabling the detection of very small infarcts. [52]. Further-
more, focal non-ischaemic scarring is also seen in a range of other condi-
tions such as dilated cardiomyopathy, aortic stenosis and sarcoidosis. The
pattern of LGE (see Fig. 1) allows discrimination between aetiologies
(e.g. ischaemic versus non-ischaemic and HFPEF ‘phenocopies’ such as
hypertrophic cardiomyopathy [HCM], amyloid, pericardial constriction),
provides prognostic information and identiﬁes vulnerable myocardium
amenable to targeted therapies [8,13,53].
In HFPEF however, the pattern of ﬁbrosis, at least in the early stages,
is typically diffuse and the signal differences between diseased and nor-
mal myocardium are less distinct, rendering the LGE technique insensi-
tive. T1 mapping and ECV quantiﬁcation techniques are promising
recent developments in CMR addressing this issue (see Fig. 2). Native
T1 values (non-contrast) are a reﬂection of myocardial tissue properties
(such as fat and water content) and may be altered in diseased states.
Estimates of T1 values encoded within pixel intensity of images enable
both focal and diffusemyocardium to be studied. T1 values can discrim-
inate pathology from normal (e.g. high T1 in diffuse ﬁbrosis and
amyloid, low T1 in iron overload) and may detect pre-clinical disease.
ECV quantiﬁcation (reliant on measurement of hematocrit, contrast
Fig. 1. Cardiac magnetic resonance imaging examples of late gadolinium enhancement patterns seen in differing aetiologies of heart failure. (a) Sub-endocardial pattern in myocardial
infarction; (b) global sub-endocardial pattern with mid-myocardial extension in amyloidosis; (c) mid-wall pattern typical of non-ischaemic dilated cardiomyopathy; (d) marked focal
“scar” in the region of maximal left ventricular hypertrophy and the superior right ventricular insertion point seen in hypertrophic cardiomyopathy.
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cardium to be further dichotomized into both intra- and extra-cellular
compartments. Differing ECV techniques have been validated against col-
lagen volume fractionmeasured at histology [54] and also tested across a
range of pathologies (HFREF, aortic stenosis [AS], HCM, amyloid)whereby
derived values discriminated between healthy controls and disease [55].
Recently in small studies, post-contrast T1 times (n=61) have shownas-
sociation with adverse outcomes (hospitalization or death) [56] and ECVFig. 2. Cardiac magnetic resonance imaging examples of “normal” appearing late gadolinium enh
(top row) and post-contrast (2nd row) T1 maps, late gadolinium enhancement (3rd row) and
(DCM); (b) amyloidosis. Adapted from Kellman et al. [101] with permission from the publishervalues (n = 62) appear to correlate with CMR measures of DD in HFPEF
[57].
Before the aforementioned techniques enter routine clinical practice
however, signiﬁcant limitations need to be addressed including: a lack
of consensus on scanning parameters and ECV techniques, the absence
of normative reference ranges across sex and age, potential confounders
of T1 values such as heart rate, respiratorymotion,magnet strength and
the lack of large scalemulti-centre studies [58]. The reproducibility of T1ancement but with diffuse abnormalities in myocardial extra-cellular volume. Pre-contrast
extra-cellular volume maps (bottom row) in (a) non-ischaemic dilated cardiomyopathy
.
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surements in most disease states and age-matched controls which is
likely to render this technique unsuitable for guiding diagnosis or ther-
apy in an individual patient [59,60].
5.1.2.1. Positron emission tomography (PET) and CT. PET (using labeled
H215O and C15O) measured perfusable tissue index (PTI) reﬂects the frac-
tion of myocardium that is perfusable by water. Fibrosis prevents rapid
exchange of water and there is moderate correlation of PTI with LGE
CMR in phenotypically similar HCM patients with preserved EF [61].
Recently, using a technique analogous to equilibrium contrast CMR [54],
CT derived quantiﬁcation of diffuse myocardial ﬁbrosis has also been val-
idated. CT based techniques appear to correlate with histology and CMR
albeit with relatively wide Bland–Altman limits of agreement [62].
5.2. Myocardial mechanics
Remodeling of the ECM compartment alters myocardial tissue
mechanics resulting in abnormalities of both diastole and systole in
HFPEF [63]. Longitudinal function is typically depressed in HFPEF and
can be measured with echocardiography (tissue Doppler) and CMR
(velocity-encoded or tissue phase mapping) [50,63]. A more detailed
assessment of LV performance can now be made using strain (or defor-
mation) analysis. Simplistically, strain imaging assesses myocardial
tissue lengthening, shortening or thickening in orthogonal planes.
Signiﬁcant correlations between early diastolic strain rates, regional
stiffness and the extent of myocardial ﬁbrosis were initially described in
animal studies [64]. Subsequently, regional strain disturbances have
demonstrated a strong relation with LV catheter derived relaxation
abnormalities and LVEDP in HCM [65]. Furthermore, the ratio of mitral
E wave velocity: global strain rate correctly predicts LVEDP and
is more accurate than E/E′ ratios in patients with preserved EF and
regional dysfunction [66]. In an exercise echocardiographic study of 56
patientswithHFPEF, both resting and exertional reductions in longitudi-
nal & radial strain as well as apical rotation were observed [67]. As
prognostic biomarkers, strain parameters (global longitudinal peak
strain and longitudinal early diastolic strain) are important predictors
of adverse outcomes (one-year follow up) in HFPEF [68].
Whereas strain measurements with echocardiography (tissue Dopp-
ler, speckle tracking) and CMR techniques (tagging) are well established
[15,50,69], recent developments in CT [70] also showpromise.With CMR,
feature tracking has recently emerged as a promising alternative to tag-
ging. In comparison, feature tracking does not necessitate prolonged
breath-holding for image acquisition, has been recently studied in
HFPEF [69] with good feasibility, has shorter analysis times and shows
good reproducibility at both 1.5- and 3-Tesla magnet strengths [71].
5.3. Haemodynamic consequences of ECM remodeling
A dilated left atrium (LA) is the haemodynamic consequence of
chronically elevated LVEDP and provides supportive evidence for
HFPEF diagnosis [3]. CMR has already superseded echocardiography
for LA volumetric measurement with superior reproducibility and
feasibility [8,12]. Beyond structural assessment, disturbances in atrial
myocardial mechanics have also been observed in HFPEF. LA dysfunc-
tion reportedly discriminates between HFPEF, hypertensive and healthy
control groups [72,73]. Using similar techniques as for LV assessment,
LA strain parameters can be measured with echocardiography [15],
CMR [74] and CT [75]. Abnormal measures of LA strain have been
noted in the HFPEF antecedent conditions of hypertension and diabetes
despite normal LA dimensions, highlighting the potential for early
disease proﬁling [76] as a marker of DD in HF, speckle tracking echocar-
diography performed better than E/E′ (AUC = 0.93 versus 0.69) and
correlated strongly with LV ﬁlling pressures [77]. Recently, global peak
longitudinal atrial strainmeasured byCMR(feature tracking) had excel-
lent feasibility (N86%), reproducibility (intra-class correlation co-efﬁcients N 0.92) and was an independent predictor of HF development
(n = 112, including n = 39 HFPEF) [74].
5.4. Detection of coronary artery disease (CAD), ischaemia and myocardial
blood ﬂow assessment
At present, the role of CAD and ischaemia in the natural history of
HFPEF is incompletely deﬁned. Not only is CAD associated with an in-
creased risk of developing HFPEF but worsens prognosis in this setting
[17]. Epidemiological studies have reported lower prevalence of CAD
in HFPEF compared to HFREF. However, pooled analysis of prospective
studies suggests that CAD is present in nearly half of all HFPEF cases
[78]. Unfortunately, themajority of these studies failed to systematically
look for CAD and were further hindered by the lack of a universal
deﬁnition and incomplete documentation in many.
Ischaemia in HFPEFmay result from macrovascular (CAD) or micro-
vascular disease (MVD). Ischaemia reduces LV chamber compliance,
increases LVEDP, causes DD and accentuates adverse ECM remodeling.
In conjunction with pressure overload typical of HFPEF, LV wall stress
is further increased, blunting sub-endocardial perfusion and coronary
reserve [9,17]. Non-invasive imaging can identify haemodynamically
signiﬁcant CAD with good sensitivity and speciﬁcity in: stress echocar-
diography (dipyridamole 85% and 89%, dobutamine 86% and 89%)
[79], adenosine SPECT (90% and 75%) [80], PET (89% and 89%), CT
(87% and 96%) andMRI (84% and 86%) [81]. CMR best detects infarction
(which may be silent) and alternatively explain symptoms (angina
equivalent), provides prognostic information and enables effective
primary and secondary prevention therapies [53,82].
Invasive (angiography) or non-invasive (TTE, CMR or PET) detection
of diminished coronary ﬂow reserve (CFR) and MVD confer adverse
prognosis in the presence or absence of CAD [83]. Furthermore, these
imaging biomarkers appear to be overrepresented in populations typi-
cal of HFPEF: increasing age, female, obese, diabetic, hypertensive and
in similar pressure overloaded conditions e.g. aortic stenosis (AS),
HCM [83]. IndeedMVD, ECM remodeling andmicrovascular endothelial
inﬂammation appear intimately linked and have recently been
proposed as a novel paradigm for HFPEF [84]. In HCM patients with
preserved EF at baseline, MVD (assessed by PET) predicted transition
to HFREF and development of symptoms [85]. Diminished myocardial
perfusion reserve (MPR) as measured by CMR may further detect pre-
clinical disease. In a recent study of severe AS patients [86], MPR inde-
pendently predicted exercise capacity and was determined by the de-
gree of ﬁbrosis and LV mass (remodeling).
5.5. Metabolic imaging
Existingnuclear andMRI techniquespermit the detection ofmetabolic
derangements of energetic status and substrate utilization (e.g. free fatty
acids) implicated in HF [87]. Irrespective of HF etiology, reductions in
energy levels (by measuring phosphocreatine) of approximately 70%
have already been shown in human and animal studies [88]. Using mag-
netic resonance spectroscopy (MRS), the association between reduced
myocardial phosphocreatine: adenosine tri-phosphate ratio (PCr:ATP)
(phosphocreatine: adenosine tri-phosphate ratio) and DD has been
shown in hypertensive patients [89] and in HFPEF during exercise [90].
Furthermore, diminished ATP ﬂux through creatine kinase (CK) may dis-
tinguish those patientswith LVHwho transition toHF [91]. Recently, CMR
hyperpolarized imaging (artiﬁcially increasingmolecular alignmentwith-
in a magnetic ﬁeld) has emerged as an exciting new methodology
allowing cardiac metabolism to be studied with dramatic increases in
signal-to-noise and early studies in HF are keenly awaited [92].
Reduced substrate uptake and oxidation may also limit cardiac
performance. Published literature provides conﬂicting data from studies
of cardiac metabolism: both fatty acid and glucose utilization appear en-
hanced in early stages but diminishes with advancing HF [87]. Several
PET radionuclide tracers that reﬂect utilization and oxidative metabolism
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HFPEF [93]. Increasing evidence implicates the role of excessive
myocardial triglyceride accumulation (steatosis) in conditions highly
prevalent in HFPEF: obesity, diabetes and pressure overload [94].
Steatosis, as quantiﬁed by MRS is independently associated with
echocardiographic measures of DD [95], strain parameters derived from
CMR tagging and correlates with histology [94].
5.6. Molecular imaging
Molecular targeting of the key markers implicated in ECM turnover
has recently shown good capabilities, albeit almost exclusively in animal
models. Potential targets studied includeMMPs, ECMproteins, the renin-
angiotensin axis and myoﬁbroblasts. Post-infarct studies have already
demonstrated the feasibility of assessing collagen deposition [96] and in-
creased probe activity closely approximates with histological ﬁndings
[97]. Although most studies have employed nuclear techniques (limited
signal from poor tissue penetration), hybrid imagingwith PET, SPECT, CT
or CMR may further improve spatial resolution, which is the current
major limitation. Cost and limited radiotracer availability are additional
factors [98].
6. Summary
This review highlights some of the potential biomarkers in HFPEF,
each offering alternative pathways for diagnosis and potential prognostic
information. Furthermore, they provide uniquemechanistic insights into
a condition that is already characterized by marked pathophysiological
diversity. Targeting biomarkers implicated across the disease spectrum,
from a molecular level to macroscopy may enable earlier detection,
better phenotyping & sub-classiﬁcation, monitoring of treatment re-
sponse and ultimately provide targeted treatment opportunities [97,
99]. Before incorporation into routine clinical practice however, these
novel plasma and imaging tests must undergo rigorous methodological
and clinical validation followed by testing in large scale, prospective
studies [4,5,60,100].
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